Why Kodiak Sciences Inc.’s (KOD) Stock Is Up 5.06%
As of Tuesday, July 21, Kodiak Sciences Inc.’s KOD share price has surged by 5.06%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Commentary & Analysis
Why Kodiak Sciences Inc.’s (KOD) Stock Is Up 5.36%
As of Friday, July 17, Kodiak Sciences Inc.’s KOD share price has surged by 5.36%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Kodiak Sciences Inc.’s (KOD) Stock Is Down 5.28%
As of Wednesday, July 15, Kodiak Sciences Inc.’s KOD share price has dipped by 5.28%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Kodiak Sciences Inc.’s (KOD) Stock Is Up 6.45%
As of Tuesday, July 14, Kodiak Sciences Inc.’s KOD share price has surged by 6.45%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Kodiak Sciences Inc.’s (KOD) Stock Is Down 5.24%
As of Friday, July 10, Kodiak Sciences Inc.’s KOD share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | KOD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,653.7 | $251.9 | 58% |
|
| Shares Out (Mil) | 61.9 | 50.8 | 53% |
|
| Institutional Ownership | 92.9% | 92.0% | 62% |
|
| Float (Mil) | 39.3 | 40.5 | 42% |
|
| Beta | 2.32 | 0.95 | 95% |
|
| Avg Daily Volume (000s) | 514 | 447 | 59% |
|
| Price Change (52-week) |
444.9% | 54.2% | 99% |
|
| Growth | KOD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (11.6%) | (9.8%) | 27% |
|
| EPS (5yr) | (8.2%) | 16.3% | 22 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (45.3%) | (15.6%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 5 | |
| Current EPS | ($0.958) | ($3.742) | ($3.117) | |
| Month Ago EPS | ($0.958) | ($3.742) | ($3.117) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($1.030) | ($4.057) | ($3.417) | |
| Year/Year Chg | 1.9% | (13.4%) | (80.2%) | |
| Financials | KOD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($231) | ($43) | 6% |
|
| EPS (TTM) | ($4.157) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($147) | ($30) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $31 | $3 | 66% |
|
| Long-Term Debt (Q1) (Mil) | $44 | $5 | 38% |
|
| Enterprise Value (Q1) (Mil) | $2,352 | $182 | 51% |
|
| Valuation | KOD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 23.48 | 2.60 | 96% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KOD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (76.4%) | (49.7%) | 7% |
|
| ROE | (208.8%) | (55.4%) | 4% |
|
| Liabilities to Assets | 63.4% | 30.3% | 58% |
|
| F-Score | 1 | 3 | 1% |
|
Kodiak Sciences Inc. did not pass any screens on 7/30/2026.
